Canaccord raised the firm’s price target on Penumbra (PEN) to $350 from $340 and keeps a Buy rating on the shares. The firm said its Q2 outperformance was driven mostly by OUS and also Embo/Access business as US thrombectomy in line with expectations. They alos noted the 2025 guidance midpoint was raised while US Thrombectomy growth, operating margins and gross margins, were all reiterated.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra, Inc. Reports Strong Q2 2025 Results
- Penumbra’s Promising Outlook: Buy Rating Amid Strong Performance and Strategic Growth Opportunities
- Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
- Penumbra raises FY25 revenue view to $1.355B-$1.370B from $1.34B-$1.36B
- Penumbra reports Q2 non-GAAP EPS 86c, consensus 82c